This revenue marks a 6% decline year-over-year from the same timeframe last year, during which the company recorded a loss of ...

Bristol Myers BMY reported better-than-expected first-quarter 2025 results. Adjusted earnings per share (EPS) of $1.80 ...

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology ...

Bristol-Myers Squibb's strong profitability, significant drug growth, and low valuation provide great upside potential. Read ...

We recently published a list of the 30 Growing Dividend Stocks with Low PE Ratios. In this article, we are going to take a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

BMY’s shares have lost 12.3% year to date ... revisions include the estimated impact of current tariffs on U.S. products shipped to China but do not account for potential pharmaceutical sector ...

Bristol Myers Squibb & Co (NYSE:BMY) reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 ...

In its upcoming report, Bristol Myers Squibb (BMY ... The average prediction of analysts places 'Net Sales- Recent LOE Products- Revlimid' at $879.35 million. The estimate indicates a change ...